BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

...II diabetes and obesity. QVT and Dexcel Pharma led the A round, and Foresite Capital, Bluebird Ventures...
...of employees: 8 Funds raised: More than $80.5 million Investors: QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures...
BioCentury | Dec 18, 2019
Financial News

With new name, Epirium snags $85M series A to develop hormonal therapy for muscular dystrophies

...hormonal pathway as well as human proof-of-concept data for its lead candidate in muscular dystrophies. BlueBird Ventures...
Items per page:
1 - 2 of 2
BioCentury | May 14, 2020
Emerging Company Profile

Kriya emerges with $80.5M A round, three gene therapies for diabetes and obesity

...II diabetes and obesity. QVT and Dexcel Pharma led the A round, and Foresite Capital, Bluebird Ventures...
...of employees: 8 Funds raised: More than $80.5 million Investors: QVT, Dexcel Pharma, Foresite Capital, Bluebird Ventures...
BioCentury | Dec 18, 2019
Financial News

With new name, Epirium snags $85M series A to develop hormonal therapy for muscular dystrophies

...hormonal pathway as well as human proof-of-concept data for its lead candidate in muscular dystrophies. BlueBird Ventures...
Items per page:
1 - 2 of 2